Quantcast
Home > Quotes > ZYME

Zymeworks Inc. Common Shares (ZYME) Quote & Summary Data

ZYME 
$15.71
*  
0.20
1.29%
Get ZYME Alerts
*Delayed - data as of Feb. 15, 2019  -  Find a broker to begin trading ZYME now
Exchange:NYSE
Industry: Health Care
Community Rating:
 
 
Symbol List Views
FlashQuotes InfoQuotes
Stock Details
Summary Quote Real-Time Quote After Hours Quote Pre-market Quote Historical Quote Option Chain
CHARTS
Basic Chart Interactive Chart
COMPANY NEWS
Company Headlines Press Releases Market Stream
STOCK ANALYSIS
Analyst Research Guru Analysis Stock Report Competitors Stock Consultant Stock Comparison
FUNDAMENTALS
Call Transcripts Annual Report Income Statement Revenue/EPS SEC Filings Short Interest Dividend History
HOLDINGS
Ownership Summary Institutional Holdings Insiders
(SEC Form 4)
 Save Stocks

Key Stock Data

1 Year Target
25.19
Today's High / Low
$ 15.75 / $ 15.34
Share Volume
27,529
90 Day Avg. Daily Volume
133,521
Previous Close
$ 15.51
52 Week High / Low
$ 29 / $ 9.57
Market Cap
502,369,164
P/E Ratio
NE
Forward P/E (1y)
NE
Earnings Per Share (EPS)
$ -0.36
Annualized Dividend
N/A
Ex Dividend Date
N/A
Dividend Payment Date
N/A
Current Yield
0 %
Beta
1.6

Intraday Chart

Shares Traded

Share Volume:
27,529
90 Day Avg. Daily Volume:
133,521

P/E Ratio

P/E Ratio:
NE
Forward P/E (1y):
NE
Earnings Per Share (EPS):
$ -0.36

Trading Range

The current last sale of $15.71 is 64.16% Higher than the 52 week low.

Intraday Last 52 Weeks
High: $ 15.75 $ 29
 Low: $ 15.34 $ 9.57

Company Description (as filed with the SEC)

Zymeworks is an innovative, clinical-stage biopharmaceutical company dedicated to the discovery, development and commercialization of next-generation multifunctional biotherapeutics. Our suite of complementary therapeutic platforms and our fully integrated drug development engine provide the flexibility and compatibility to precisely engineer and develop highly differentiated product candidates. These capabilities have resulted in multiple wholly owned product candidates with the potential to drive superior outcomes in large underserved and unaddressed patient populations, as further described below. Our lead product candidate, ZW25, is a novel bispecific (dual-targeting) antibody which targets two distinct domains of the human epidermal growth factor receptor 2, or HER2.  ... More ...  


Risk Grade

Where does ZYME fit in the risk graph?


Risk Grade Scale

Consensus Recommendation

Analyst Info